Chip Davis Discusses HDA’s 2023 Priorities in Annual Chain Drug Review ColumnJanuary 09, 2023 With the welcoming of the new year and 118th Congress, HDA’s President and CEO Chip Davis penned an overview of the association’s 2023 priorities for the January 9 issue of Chain Drug Review. The piece, a part of the publication’s annual “Health Care Outlook” feature, underscores the clear value proposition of the healthcare distribution industry and shares the range of issues that HDA leadership plan to focus on in the coming months, which include supply chain resilience and health equity issues, drug pricing and affordability, and DSCSA Implementation, among others.
More information on HDA’s policy efforts can be found here.
When discussing supply chain resilience, Davis mentions the important conversations around the upcoming commercialization of COVID-19 vaccines and therapeutics and the readiness of members to continue serving as partners in distribution of these vital products.
Further, Davis notes how HDA’s recent relocation to Washington, D.C., will help with communicating the role and value of the distribution industry, saying “Our relocation will offer additional opportunities for us to welcome our members to the nation’s capital to clearly illustrate our core expertise to the lawmakers of the new Congress, regulators, thought leaders and our supply chain partners.”
Read the full column to learn more.